Biomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc)

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/3235

Title:	Biomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc)
Authors:	Saad, F. Armstrong, A. J. Thiery-Vuillemin, A. Oya, M. Shore, N. D. Procopio, G. Arslan, C.
Publisher:	Elsevier
Abstract:	[Abstract Not Available]
Description:	Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK
URI:	https://hdl.handle.net/20.500.14365/3235
ISSN:	0923-7534 1569-8041
Appears in Collections:	WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

File	Size	Format
2340.pdf Restricted Access	157.18 kB	Adobe PDF	View/Open

CORE Recommender

9

checked on Apr 2, 2025

64

checked on Mar 31, 2025

6

checked on Mar 31, 2025

Check